These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

57 related items for PubMed ID: 7196238

  • 21. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects.
    Henney HR, Shah J.
    Clin Ther; 2007 Apr; 29(4):661-9. PubMed ID: 17617289
    [Abstract] [Full Text] [Related]

  • 22. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M, Retzow A, Vens-Cappell B.
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [Abstract] [Full Text] [Related]

  • 23. Absolute bioavailability of amezinium. A cross-over study after i.v. and p.o. application.
    Kaumeier S, Kehrhahn OH, Morgenthaler H, Neugebauer G.
    Arzneimittelforschung; 1981 Feb; 31(9a):1653-7. PubMed ID: 7197980
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers.
    Hatorp V, Oliver S, Su CA.
    Int J Clin Pharmacol Ther; 1998 Dec; 36(12):636-41. PubMed ID: 9877000
    [Abstract] [Full Text] [Related]

  • 27. A pharmacokinetic and pharmacodynamic comparison of desmopressin administered as whole, chewed and crushed tablets, and as an oral solution.
    Argenti D, Ireland D, Heald DL.
    J Urol; 2001 May; 165(5):1446-51. PubMed ID: 11342894
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects.
    Möller A, Iwasaki K, Kawamura A, Teramura Y, Shiraga T, Hata T, Schäfer A, Undre NA.
    Drug Metab Dispos; 1999 Jun; 27(6):633-6. PubMed ID: 10348790
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Absorption of fenthiazac applied to the skin].
    Pedrazzini S.
    Boll Chim Farm; 1978 Jan; 117(1):19-26. PubMed ID: 743349
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Description of the pharmacokinetic behaviour of Etozolin and its main metabolite (author's transl)].
    Gladigau V, Vollmer KO.
    Arzneimittelforschung; 1977 Jan; 27(9a):1786-99. PubMed ID: 578768
    [No Abstract] [Full Text] [Related]

  • 38. Metabolism of fentiazac.
    Fumero S, Mondino A, Silvestri S, Zanolo G, De Marchi G, Pedrazzini S.
    Arzneimittelforschung; 1980 Jan; 30(8):1253-6. PubMed ID: 7192138
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Spectrophotometric study of the in vitro liberation of fentiazac acid].
    Leon MJ, Fauli C.
    Boll Chim Farm; 1984 Nov; 123(11):505-11. PubMed ID: 6532478
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 3.